Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination

Ophthalmology

Volumn 110, Issue 7, 2003, Pages 1357-1360

  Konstas, Anastasios G P ^a   Papapanos, Panayiotis ^b   Tersis, Ioannis ^a   Houliara, Dimitra ^b   Stewart, William C ^c,d  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b Gen Perfectural Hosp of Korinthos   (Greece)

^c University of South Carolina   (United States)

^d UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL; LATANOPROST;

ADULT; AGED; ARTICLE; ASTHMA; BITTER TASTE; BURNING SENSATION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE DISEASE; EYE REDNESS; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PATIENT SATISFACTION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PRURITUS; RETINA PIGMENT EPITHELIOPATHY; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038492793     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00404-4     Document Type: Article

References (29)

1. Smith SL, Pruitt CA, Sine CS, et al. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 1999;77:189-92.
2. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1999;106(12 Suppl):17-24.
3. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/ timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998;82:1249-53.
4. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 1999;106(12 Suppl):10-6.
5. Konstas AGP, Maltezos AC, Gandi S, et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999;128:15-20.
6. Konstas AGP, Lake S, Maltezos AC, et al. Twenty-four hour intraocular pressure reduction with latanoprost compared with pilocarpine as third-line therapy in exfoliation glaucoma. Eye 2001;15:59-62.
7. Orzalesi N, Rossetti I, Bottoli A, et al. Comparison of latanoprost, brimonidine and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension: Acta Ophthalmol Scand Suppl 2002;236:55.
8. Konstas AGP, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:182-5.
9. Konstas AGP, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 1997;115:975-9.
10. Book SA. Essentials of Statistics. New York: McGrawHill, 1978, 117-22, 205-15.
11. Mundorf TK, Cate EA, Sine CS, et al. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocular Pharmacol Ther 1998;14:129-35.
12. Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol (Copenh) 1987;65:618-21.
13. Stewart WC, Day DG, Stewart JA, et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;131:631-5.
14. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York: McGrawHill, 1956:63-7.
15. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992;17:691704.
16. Nilsson SFE, Samuelsson M, Bill A, Stjernschantz J. Increased uveosclerat outflow as a possible mechanism of ocular hypotension caused by prostaglandin F-2-alfa-1-isopropilester in the cynomolgus monkey. Exp Eye Res 1989;48:707-96.
17. 2a increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989;49:389-402.
18. Kerstetter JR, Brubaker RF, Wilson SE, Kullerstrand LJ. Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am J Ophthalmol 1988;105:30-4.
19. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2-alpha analogue, on aqueous humor dynamics in human eyes. Ophthalmology 1993;100:1297-304.
20. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52.
21. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47.
22. Watson P, Stjernschantz J, A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-37.
23. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophthalmol 1998;126:390-9.
24. Stewart WC. Current and Future Glaucoma Therapy. Duluth, GA: Ciba Vision Ophthalmics, 1997:1-43.
25. Smith SL, Pruitt CA, Sine CS, Hudgins AC, et al. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999;77:668-72.
26. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106:1024-9.
27. Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am J Ophthalmol 1999;127:531-6.
28. Stewart WC. Perspectives in the medical treatment of glaucoma. Curr Opin Ophthalmol 1999;10:99-108.
29. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxotol. International Dorzolamide Study Group. Arch Ophthalmol 1995;113:1009-16.